Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters











Database
Language
Publication year range
1.
Nature ; 550(7674): 114-118, 2017 10 05.
Article in English | MEDLINE | ID: mdl-28953874

ABSTRACT

The ability to directly uncover the contributions of genes to a given phenotype is fundamental for biology research. However, ostensibly homogeneous cell populations exhibit large clonal variance that can confound analyses and undermine reproducibility. Here we used genome-saturated mutagenesis to create a biobank of over 100,000 individual haploid mouse embryonic stem (mES) cell lines targeting 16,970 genes with genetically barcoded, conditional and reversible mutations. This Haplobank is, to our knowledge, the largest resource of hemi/homozygous mutant mES cells to date and is available to all researchers. Reversible mutagenesis overcomes clonal variance by permitting functional annotation of the genome directly in sister cells. We use the Haplobank in reverse genetic screens to investigate the temporal resolution of essential genes in mES cells, and to identify novel genes that control sprouting angiogenesis and lineage specification of blood vessels. Furthermore, a genome-wide forward screen with Haplobank identified PLA2G16 as a host factor that is required for cytotoxicity by rhinoviruses, which cause the common cold. Therefore, clones from the Haplobank combined with the use of reversible technologies enable high-throughput, reproducible, functional annotation of the genome.


Subject(s)
Biological Specimen Banks , Genomics/methods , Haploidy , Mouse Embryonic Stem Cells/metabolism , Mutation , Animals , Blood Vessels/cytology , Cell Lineage/genetics , Common Cold/genetics , Common Cold/virology , Genes, Essential/genetics , Genetic Testing , HEK293 Cells , Homozygote , Humans , Mice , Mouse Embryonic Stem Cells/cytology , Neovascularization, Physiologic/genetics , Phospholipases A2, Calcium-Independent/genetics , Phospholipases A2, Calcium-Independent/metabolism , Rhinovirus/pathogenicity
2.
Stem Cells Dev ; 24(1): 115-31, 2015 Jan 01.
Article in English | MEDLINE | ID: mdl-25244528

ABSTRACT

Mesenchymal stromal cells (MSCs) are promising tools for therapeutic revascularization of ischemic tissues and for support of vessel formation in engineered tissue constructs. Recently, we could show that avascular-derived MSCs from placental amnion release soluble factors that exhibit survival-enhancing effects on endothelial cells (ECs). We hypothesize that MSCs derived from placental blood vessels might have even more potent angiogenic effects. Therefore, we isolated and characterized MSCs from placental chorionic blood vessels (bv-MSCs) and tested their angiogenic potential in comparison to amnion-derived avascular MSCs (av-MSCs). bv-MSCs express a very similar surface marker profile compared with av-MSCs and could be differentiated toward the adipogenic and osteogenic lineages. bv-MSCs exert immunosuppressive properties on peripheral blood mononuclear cells, suggesting that they are suitable for cell transplantation settings. Conditioned medium (Cdm) from av-MSCs and bv-MSCs significantly enhanced EC viability, whereas only Cdm from bv-MSCs significantly increased EC migration and network formation (Matrigel assay). Angiogenesis array analysis of av- and bv-MSC-Cdm revealed a similar secretion pattern of angiogenic factors, including angiogenin, interleukins-6 and -8, and tissue inhibitors of matrix metalloproteinase-1 and 2. Enzyme-linked immunosorbent assay analysis showed that, in contrast to av-MSCs, bv-MSCs secreted vascular endothelial growth factor. In direct coculture with bv-MSCs, ECs showed a significantly increased formation of vessel-like structures compared with av-MSCs. With regard to therapeutic treatment, bv-MSCs and particularly their Cdm might be valuable to stimulate angiogenesis especially in ischemic tissues. av-MSCs and their Cdm could be beneficial in conditions when it is required to promote the survival and stabilization of blood vessels without the risk of unmeant angiogenesis.


Subject(s)
Amnion , Blood Vessels , Cell Differentiation , Endothelial Cells , Mesenchymal Stem Cells , Neovascularization, Physiologic , Placenta , Adult , Amnion/cytology , Amnion/metabolism , Angiogenesis Inducing Agents/metabolism , Blood Vessels/cytology , Blood Vessels/metabolism , Cell Survival , Culture Media, Conditioned , Endothelial Cells/cytology , Endothelial Cells/metabolism , Female , Humans , Mesenchymal Stem Cell Transplantation , Mesenchymal Stem Cells/cytology , Mesenchymal Stem Cells/metabolism , Placenta/blood supply , Placenta/cytology , Placenta/metabolism , Pregnancy
3.
Angew Chem Int Ed Engl ; 53(35): 9198-202, 2014 Aug 25.
Article in English | MEDLINE | ID: mdl-25045108

ABSTRACT

It is becoming increasingly clear that nature uses RNAs extensively for regulating vital functions of the cell, and short sequences are frequently used to suppress gene expression. However, controlling the concentration of small molecules intracellularly through designed RNA sequences that fold into ligand-binding structures is difficult. The development of "endless", a triplex-based folding motif that can be expressed in mammalian cells and binds the second messenger 3',5'-cyclic guanosine monophosphate (cGMP), is described. In vitro, DNA or RNA versions of endless show low micromolar to nanomolar dissociation constants for cGMP. To test its functionality in vivo, four endless RNA motifs arranged in tandem were co-expressed with a fluorescent cGMP sensor protein in murine vascular smooth muscle cells. Nitric oxide induced endogenous cGMP signals were suppressed in endless-expressing cells compared to cells expressing a control motif, which suggests that endless can act as a genetically encoded cGMP sink to modulate signal transduction in cells.


Subject(s)
Muscle, Smooth, Vascular/metabolism , Nucleotide Motifs/genetics , Purines/metabolism , Animals , Gene Expression , Mice , Muscle, Smooth, Vascular/cytology , Purines/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL